Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+

  Prostate Cancer

  Free Subscription


1 Acta Radiol
1 Cancer Lett
1 Cancer Res
1 Eur Radiol
5 Eur Urol
1 J Cell Physiol
2 J Nucl Med
3 J Urol
2 Oncogene
1 Oncology (Williston Park)
1 PLoS One
2 Prostate
3 Urol Int
2 Urology

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Acta Radiol

  1. LEE CH
    Quantitative T2-mapping using MRI for detection of prostate malignancy: a systematic review of the literature.
    Acta Radiol. 2019;60:1181-1189.
    PubMed     Text format    

    Cancer Lett

  2. XU Y, Deng J, Wang G, Zhu Y, et al
    Long Non-coding RNAs in Prostate Cancer: Functional Roles and Clinical Implications.
    Cancer Lett. 2019 Aug 26. pii: S0304-3835(19)30447.
    PubMed     Text format     Abstract available

    Cancer Res

  3. CAI C, Han D, Chen S, Han W, et al
    ZBTB7A mediates the transcriptional repression activity of the androgen receptor in prostate cancer.
    Cancer Res. 2019 Aug 23. pii: 0008-5472.CAN-19-0815.
    PubMed     Text format     Abstract available

    Eur Radiol

  4. ALDOJ N, Lukas S, Dewey M, Penzkofer T, et al
    Semi-automatic classification of prostate cancer on multi-parametric MR imaging using a multi-channel 3D convolutional neural network.
    Eur Radiol. 2019 Aug 29. pii: 10.1007/s00330-019-06417.
    PubMed     Text format     Abstract available

    Eur Urol

  5. DROST FH, Nieboer D, Morgan TM, Carroll PR, et al
    Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.
    Eur Urol. 2019 Aug 23. pii: S0302-2838(19)30602.
    PubMed     Text format     Abstract available

  6. HOYLE AP, Ali A, James ND, Cook A, et al
    Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
    Eur Urol. 2019 Aug 22. pii: S0302-2838(19)30620.
    PubMed     Text format     Abstract available

  7. RAMNARINE VR, Kobelev M, Gibb EA, Nouri M, et al
    The evolution of long noncoding RNA acceptance in prostate cancer initiation and progression, and its clinical utility in disease management.
    Eur Urol. 2019 Aug 22. pii: S0302-2838(19)30601.
    PubMed     Text format     Abstract available

  8. KELLOKUMPU-LEHTINEN PL, Hjalm-Eriksson M, Thellenberg-Karlsson C, Astrom L, et al
    Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial.
    Eur Urol. 2019 Aug 20. pii: S0302-2838(19)30654.
    PubMed     Text format     Abstract available

  9. DONZELLI A, Castelluzzo G, Giudicatti G
    Re: Jonas Hugosson, Monique J. Roobol, Marianne Mansson, et al. A 16-yr Follow-up of the European Randomized Study of Screening for Prostate Cancer. Eur Urol 2019;76:43-51: Mortality in the Age Group >/=70yr and the Case of Italy.
    Eur Urol. 2019 Aug 20. pii: S0302-2838(19)30606.
    PubMed     Text format    

    J Cell Physiol

  10. SHA J, Han Q, Chi C, Zhu Y, et al
    Upregulated KDM4B promotes prostate cancer cell proliferation by activating autophagy.
    J Cell Physiol. 2019 Aug 29. doi: 10.1002/jcp.29117.
    PubMed     Text format     Abstract available

    J Nucl Med

  11. ROWE SP, Li X, Trock BJ, Werner RA, et al
    Prospective Comparison of PET Imaging with PSMA-targeted (18)F-DCFPyL versus Na(18)F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer.
    J Nucl Med. 2019 Aug 26. pii: jnumed.119.227793. doi: 10.2967/jnumed.119.227793.
    PubMed     Text format     Abstract available

  12. RAHBAR K, Morris MJ
    Is the "VISION" of Radioligand Therapy for Prostate Cancer becoming reality? An Overview of the Phase III trial and the Importance for the Future of Theranostics.
    J Nucl Med. 2019 Aug 26. pii: jnumed.119.234054. doi: 10.2967/jnumed.119.234054.
    PubMed     Text format    

    J Urol

  13. PISANSKY TM, Thompson IM, Valicenti RK, D'Amico AV, et al
    Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO/AUA Guideline Amendment 2018-2019.
    J Urol. 2019;202:533-538.
    PubMed     Text format     Abstract available

  14. VECCIA A, Antonelli A, Francavilla S, Porpiglia F, et al
    Minimally Invasive Radical Prostatectomy after Previous Bladder Outlet Surgery: A Systematic Review and Pooled Analysis of Comparative Studies.
    J Urol. 2019;202:511-517.
    PubMed     Text format     Abstract available

  15. BALAKRISHNAN AS, Cowan JE, Cooperberg MR, Shinohara K, et al
    Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance.
    J Urol. 2019;202:506-510.
    PubMed     Text format     Abstract available


  16. GANGULY SS, Hostetter G, Tang L, Frank SB, et al
    Notch3 promotes prostate cancer-induced bone lesion development via MMP-3.
    Oncogene. 2019 Aug 29. pii: 10.1038/s41388-019-0977.
    PubMed     Text format     Abstract available

  17. ZHU S, Zhao D, Li C, Li Q, et al
    BMI1 is directly regulated by androgen receptor to promote castration-resistance in prostate cancer.
    Oncogene. 2019 Aug 28. pii: 10.1038/s41388-019-0966.
    PubMed     Text format     Abstract available

    Oncology (Williston Park)

  18. SALEH N
    Current Clinical Trials in Prostate Cancer.
    Oncology (Williston Park). 2019;33.
    PubMed     Text format    

    PLoS One

  19. RADTKE JP, Giganti F, Wiesenfarth M, Stabile A, et al
    Prediction of significant prostate cancer in biopsy-naive men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS.
    PLoS One. 2019;14:e0221350.
    PubMed     Text format     Abstract available


  20. CACKOWSKI FC, Wang Y, Decker JT, Sifuentes C, et al
    Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer.
    Prostate. 2019;79:1715-1727.
    PubMed     Text format     Abstract available

  21. SHISHODIA G, Koul S, Koul HK
    Protocadherin 7 is overexpressed in castration resistant prostate cancer and promotes aberrant MEK and AKT signaling.
    Prostate. 2019 Aug 26. doi: 10.1002/pros.23898.
    PubMed     Text format     Abstract available

    Urol Int

  22. ROSENHAMMER B, Niessen C, Rotzinger L, Reiss J, et al
    Oncological Outcome and Value of Postoperative Magnetic Resonance Imaging after Focal High-Intensity Focused Ultrasound Therapy for Prostate Cancer.
    Urol Int. 2019 Aug 29:1-9. doi: 10.1159/000502553.
    PubMed     Text format     Abstract available

  23. PORCARO AB, Tafuri A, Sebben M, Novella G, et al
    Prostate Volume Index Is Able to Differentiate between Prostatic Chronic Inflammation and Prostate Cancer in Patients with Normal Digital Rectal Examination and Prostate-Specific Antigen Values <10 ng/mL: Results of 564 Biopsy Naive Cases.
    Urol Int. 2019 Aug 29:1-8. doi: 10.1159/000502659.
    PubMed     Text format     Abstract available

  24. MIYOSHI Y, Sakamoto S, Kawahara T, Uemura K, et al
    Correlation between Automated Bone Scan Index Change after Cabazitaxel and Survival among Men with Castration-Resistant Prostate Cancer.
    Urol Int. 2019 Aug 28:1-6. doi: 10.1159/000502655.
    PubMed     Text format     Abstract available


  25. PENG LC, Mian OY, Lakshminarayanan P, Huang P, et al
    Analysis of Spatial Dose-Volume Relationships and Decline in Sexual Function Following Permanent Brachytherapy for Prostate Cancer.
    Urology. 2019 Aug 24. pii: S0090-4295(19)30732.
    PubMed     Text format     Abstract available

  26. JOHNSTON MJ, Emara A, Noureldin M, Bott S, et al
    Focal high-intensity focussed ultrasound partial gland ablation for the treatment of localised prostate cancer: a report of medium-term outcomes from a single-centre in the United Kingdom.
    Urology. 2019 Aug 23. pii: S0090-4295(19)30730.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.